Hidradenitis Suppurativa: A Chronic Skin Battle

davidcracc
Email: hmason@delveinsight.com

posted on 2 weeks ago — updated on 1 second ago

6
views

Hidradenitis Suppurativa (HS) is a chronic inflammatory skin disorder characterized by painful abscesses and tunnels beneath the skin. It commonly affects areas where skin surfaces rub together, such as the armpits, groin, buttocks, and under the breasts. The condition typically worsens ov

Get a snapshot of the 7MM landscape—view the infographic now!: <a href="https://www.delveinsight.com/infographics/hidradenitis-suppurativa-market?utm_source=infographics&utm_medium=promotion&utm_campaign=hpr">Click Here</a>Hidradenitis Suppurativa Epidemiological Segmentation The epidemiological segmentation of Hidradenitis Suppurativa across the 7MM from 2020 to 2034 covers:<ul><li dir="ltr" aria-level="1">Total prevalent cases of Hidradenitis Suppurativa in the US </li><li dir="ltr" aria-level="1">Total diagnosed prevalent cases in the US </li><li dir="ltr" aria-level="1">Gender-specific cases in the US </li><li dir="ltr" aria-level="1">Age-specific cases in the US </li><li dir="ltr" aria-level="1">Stage-specific cases in the US </li><li dir="ltr" aria-level="1">Treated prevalent cases in the US </li></ul>Hidradenitis Suppurativa Epidemiology In 2023, the epidemiological trends for Hidradenitis Suppurativa across the 7MM were as follows:<ul><li dir="ltr" aria-level="1">Approximately 6.2 million total prevalent cases of HS were recorded across the 7MM, with numbers expected to rise by 2034. </li><li dir="ltr" aria-level="1">The US accounted for the highest number of diagnosed cases, with nearly 877,600 in 2023. </li><li dir="ltr" aria-level="1">Within the EU4 and the UK, Germany reported the highest diagnosed cases, whereas Spain had the lowest. </li><li dir="ltr" aria-level="1">HS was more prevalent in females (~75%) compared to males (~25%) in the US, EU4, and UK; in contrast, in Japan, males constituted nearly 70% of cases, with females making up about 30%. </li><li dir="ltr" aria-level="1">The 30–39 age group was the most affected in the US, representing nearly 26% of diagnosed cases. </li><li dir="ltr" aria-level="1">Among the Hurley stages, Stage I was the most common, with roughly 480,000 cases in the US in 2023.</li></ul>You’ve seen the key stats—now discover what’s driving them: <a href="https://www.delveinsight.com/report-store/hidradenitis-suppurativa-market?utm_source=infographics&utm_medium=promotion&utm_campaign=hpr">Click Here </a>Hidradenitis Suppurativa Market The total market size for Hidradenitis Suppurativa in the 7MM was approximately USD 1.4 billion in 2023.Hidradenitis Suppurativa Market Drivers<ul><li dir="ltr" aria-level="1">The introduction of novel therapies such as Povorcitinib (INCB054707), Izokibep, and RINVOQ (upadacitinib) is expected to offer more targeted treatment options, improving patient outcomes and driving market growth. </li><li dir="ltr" aria-level="1">Increasing awareness of HS and enhanced diagnostic techniques are likely to enable earlier diagnosis and treatment, thus expanding the market for HS therapies. </li></ul><a href="https://www.delveinsight.com/report-store/hidradenitis-suppurativa-market?utm_source=infographics&utm_medium=promotion&utm_campaign=hpr">Hidradenitis Suppurativa Market</a> Barriers<ul><li dir="ltr" aria-level="1">The complexity in diagnosing and managing HS due to its heterogeneous presentation and progression poses challenges in developing standardized treatment protocols and conducting clinical trials. </li><li dir="ltr" aria-level="1">The high cost of new therapies and limited access in certain regions may restrict the broad adoption of these treatments. </li></ul>Hidradenitis Suppurativa Emerging Therapies<ul><li dir="ltr" aria-level="1">Povorcitinib (INCB054707) </li><li dir="ltr" aria-level="1">Izokibep </li><li dir="ltr" aria-level="1">RINVOQ (upadacitinib) </li><li dir="ltr" aria-level="1">Lutikizumab (ABT-981) </li><li dir="ltr" aria-level="1">Sonelokimab (M1095) </li><li dir="ltr" aria-level="1">Spesolimab </li><li dir="ltr" aria-level="1">Brepocitinib </li><li dir="ltr" aria-level="1">Eltrekibart </li><li dir="ltr" aria-level="1">Ruxolitinib 1.5% Cream </li><li dir="ltr" aria-level="1">SAR-444656/KT-474 </li><li dir="ltr" aria-level="1">Orismilast </li><li dir="ltr" aria-level="1">And others </li></ul>Hidradenitis Suppurativa Key Players<ul><li dir="ltr" aria-level="1">Incyte Corporation </li><li dir="ltr" aria-level="1">ACELYRIN </li><li dir="ltr" aria-level="1">AbbVie </li><li dir="ltr" aria-level="1">MoonLake Immunotherapeutics </li><li dir="ltr" aria-level="1">Boehringer Ingelheim </li><li dir="ltr" aria-level="1">Priovant Therapeutics </li><li dir="ltr" aria-level="1">Eli Lilly </li><li dir="ltr" aria-level="1">Sanofi </li><li dir="ltr" aria-level="1">Kymera Therapeutics </li><li dir="ltr" aria-level="1">UNION Therapeutics </li><li dir="ltr" aria-level="1">And others</li></ul>Want more data like this? Get the infographic now: <a href="https://www.delveinsight.com/infographics/hidradenitis-suppurativa-market?utm_source=infographics&utm_medium=promotion&utm_campaign=hpr">Click Here </a>